Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported): September 12, 2007
NEKTAR
THERAPEUTICS
(Exact
name of Registrant as specified in its charter)
|
Delaware
(State
or other jurisdiction
of
incorporation)
|
0-24006
(Commission
File
Number)
|
94-3134940
(IRS
Employer
Identification
No.)
|
201
Industrial Road
San
Carlos, California 94070
(Address
of principal executive offices and Zip Code)
Registrant’s
telephone number, including area code: (650) 631-3100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
September 18, 2007, the company announced that David Johnston, Ph.D., Senior
Vice President of Research and Development, will be leaving the company in
connection with the creation of New PEGylation and Pulmonary Research Units
effective on September 12, 2007. The company expects to enter into a transition
and
separation agreement with Mr. Johnston, the terms of which have not yet
been finalized.
Item
7.01. Regulation FD Disclosure.
On
September 18, 2007, the company announced via press release certain
organizational changes. The company hereby incorporates by reference into this
Item 7.01 the information set forth in such press release, a copy of which
is furnished as Exhibit 99.1 to this Current Report. Pursuant to the rules
and regulations of the SEC, such exhibit and the information set forth therein
and herein are deemed to be furnished and shall not be deemed to be “filed”
under the Securities Exchange Act of 1934, as amended.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits:
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press
release titled “Nektar Therapeutics Creates New PEGylation and Pulmonary
Research Units to Drive Innovative Technology-Based Product Pipeline,”
issued on September 18, 2007.
|
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
By:
|
/s/
Gil M. Labrucherie
|
| |
|
Gil
M. Labrucherie
General
Counsel and Secretary
|
| |
|
|
| |
Date:
|
September
18, 2007
|